Interference with Megalin Expression/endocytic Function by Montelukast Mitigates Gentamicin Nephrotoxicity: Downregulation of ClC-5 Expression
Overview
Affiliations
Megalin receptor-mediated endocytosis participates a crucial role in gentamicin (GM) uptake, accumulation, and toxicity. In this study, we investigated the potential effects of montelukast (MLK) on megalin expression/endocytic function against GM nephrotoxicity. Male Wistar rats were administered GM (120 mg/kg; i.p.) daily in divided doses along 4 hr; 30 mg/kg/hr; for 7 days. MLK (30 mg/kg/day) was orally administered 7 days before and then concurrently with GM. The protein expressions of megalin and chloride channel-5 (ClC-5); one of the essential regulators of megalin endocytic function; were determined by Western blotting. Besides, the endocytic function of megalin was evaluated by the uptake of bovine serum albumin labeled with fluorescein isothiocyanate (FITC-BSA) into proximal tubular epithelial cells. Moreover, kidney function biomarkers (Cr, BUN, GFR, KIM-1, cystatin-C) and apoptosis markers (p-AKT1, cleaved caspase-3) were estimated. Co-treatment with MLK downregulated ClC-5 expression leading to reduced recycling of megalin to the plasma membrane, reduced expression, and so impaired endocytic function that was evidenced by reduced uptake of FITC-BSA in proximal tubular epithelial cells. The protein expression of the apoptotic executioner cleaved caspase-3 was significantly reduced, while that of the antiapoptotic p-AKT1 was elevated. These results were confirmed by the improvement of kidney functions and histological findings. Our data suggest that MLK could interfere with megalin expression/endocytic function that could be attributed to downregulation of ClC-5 protein expression. That eventually reduces renal cell apoptosis and improves kidney functions after GM administration without affecting the antibacterial activity of GM. Therefore, reduced expression of ClC-5 and interference with megalin expression/endocytic function by MLK could be an effective strategy against GM nephrotoxicity.
The renoprotective potential of montelukast: a scoping review.
Sarmadian R, Gilani A, Mehrtabar S, Mahrokhi Koushemehr S, Hakimzadeh Z, Yousefichaijan P Ann Med Surg (Lond). 2024; 86(6):3568-3576.
PMID: 38846849 PMC: 11152873. DOI: 10.1097/MS9.0000000000002085.
Abdel-Rahman D, Messiha B, Ali F, Azouz A Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(5):3141-3153.
PMID: 37891258 PMC: 11074040. DOI: 10.1007/s00210-023-02787-w.
Balaha M, Alamer A, Eisa A, Aljohani H Antibiotics (Basel). 2023; 12(5).
PMID: 37237729 PMC: 10215741. DOI: 10.3390/antibiotics12050826.